IDEAS home Printed from
MyIDEAS: Log in (now much improved!) to save this paper

Corporate Governance and Firm Strategy in the Pharmaceutical Industry

Listed author(s):
  • Steven Casper
  • Catherine Matraves

Using the case of the pharmaceutical industry, this paper assesses how the leading German and UK firms are adapting to changes in their competitive environment, at both the national and international level. We attempt to link how firms create governance structures (management decision-making, the organisation of the R&D process, etc.), and the national system of innovation, impact the innovation strategies adopted in leading German and UK firms. Our results show that first, the firm competencies created in order to compete globally may still originate within national economies, in part because the generation of R&D remains relatively national. Second, towards the end of the 1970s, the scientific basis in the pharmaceutical industry began to change rapidly. The evidence presented shows that UK firms rapidly developed new competencies in biotechnology and other research areas in response to the structural changes. However, German firms tended, until very recently, to maintain and in some cases strengthen competencies in traditional research methods based on organic chemistry. ZUSAMMENFASSUNG - (Corporate Governance und Unternehmensstrategie in der pharmazeutischen Industrie) Am Beispiel der pharmazeutischen Industrie wird in diesem Beitrag aufgezeigt, wie führende deutsche und britische Firmen sich an Änderungen in ihrer Unternehmensumwelt anpassen, sowohl der nationalen wie auch der internationalen Umwelt. Es wird gezeigt, wie die Unternehmen Governance-Strukturen (Managemententscheidungen, die Organisation von FuE-Prozessen etc.) schaffen und wie nationale Innovationssysteme die Innovationsstrategien beeinflussen, die von führenden deutschen und britischen Firmen verfolgt werden. Erstens gelangt die Studie zu dem Ergebnis, daß die Kompetenz der Unternehmen so ausgerichtet wurde, daß sie für den globalen Wettbewerb fit sind, aber ihre Wurzeln dennoch innerhalb der nationalen Volkswirtschaften behalten, teilweise deshalb, weil FuE verhältnismäßig national fundiert ist. Zweitens begann zum Ende der siebziger Jahre eine dramatische Änderung in der wissenschaftlichen Basis der pharmazeutischen Industrie. Diese Evidenz zeigt, daß britische Firmen rasch neue Kompetenz in Biotechnologie und anderen Forschungsbereichen entwickelten, um auf die Änderungen zu reagieren. Deutsche Unternehmen tendierten jedoch noch bis vor kurzem dazu, ihre bisherige Kompetenz beizubehalten und in manchen Fällen in traditionellen Forschungsbereichen, basierend auf organischer Chemie, sogar zu verstärken.

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL:
Download Restriction: no

Paper provided by Wissenschaftszentrum Berlin (WZB), Research Unit: Competition and Innovation (CIG) in its series CIG Working Papers with number FS IV 97-20.

in new window

Length: 28 pages
Date of creation: Sep 1997
Handle: RePEc:wzb:wzebiv:fsiv97-20
Contact details of provider: Postal:
Reichpietschufer 50, 10785 Berlin, Germany

Phone: (++49)(30) 25491-441
Fax: (++49)(30) 25491-442
Web page:

More information through EDIRC

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

in new window

  1. Rebecca Henderson & Iain Cockburn, 1996. "Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery," RAND Journal of Economics, The RAND Corporation, vol. 27(1), pages 32-59, Spring.
  2. David J. TEECE, 2008. "Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy," World Scientific Book Chapters,in: The Transfer And Licensing Of Know-How And Intellectual Property Understanding the Multinational Enterprise in the Modern World, chapter 5, pages 67-87 World Scientific Publishing Co. Pte. Ltd..
  3. Henderson, Rebecca., 1994. "The evolution of integrative capability : innovation in cardiovascular drug discovery," Working papers 3711-94., Massachusetts Institute of Technology (MIT), Sloan School of Management.
  4. Joaquim Oliveira Martins & Stefano Scarpetta & Dirk Pilat, 1996. "Mark-Up Ratios in Manufacturing Industries: Estimates for 14 OECD Countries," OECD Economics Department Working Papers 162, OECD Publishing.
  5. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
  6. Vitols, Sigurt, 1995. "Corporate governance versus economic governance: banks and industrial restructuring in the US and Germany," Discussion Papers, Research Unit: Economic Change and Employment FS I 95-310, Social Science Research Center Berlin (WZB).
  7. Masahiko Aoki, 2013. "Toward an Economic Model of the Japanese Firm," Chapters,in: Comparative Institutional Analysis, chapter 18, pages 315-341 Edward Elgar Publishing.
  8. Patel, Pari, 1995. "Localised Production of Technology for Global Markets," Cambridge Journal of Economics, Oxford University Press, vol. 19(1), pages 141-153, February.
  9. Mark Lehrer, 1997. "German Industrial Strategy in Turbulence: Corporate Governance and Managerial Hierarchies in Lufthansa," Industry and Innovation, Taylor & Francis Journals, vol. 4(1), pages 115-140.
  10. Iain Cockburn & Rebecca Henderson, 1997. "Public-Private Interaction and the Productivity of Pharmaceutical Research," NBER Working Papers 6018, National Bureau of Economic Research, Inc.
  11. Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July.
  12. Kenney, Martin, 1986. "Schumpeterian innovation and entrepreneurs in capitalism: A case study of the U.S. biotechnology industry," Research Policy, Elsevier, vol. 15(1), pages 21-31, February.
  13. Pavitt, Keith, 1991. "What makes basic research economically useful?," Research Policy, Elsevier, vol. 20(2), pages 109-119, April.
  14. Matraves, Catherine, 1999. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 47(2), pages 169-194, June.
  15. Henderson, Rebecca. & Cockburn, Iain., 1994. "Measuring competence? : exploring firm effects in pharmaceutical research," Working papers 3712-94., Massachusetts Institute of Technology (MIT), Sloan School of Management.
Full references (including those not matched with items on IDEAS)

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

When requesting a correction, please mention this item's handle: RePEc:wzb:wzebiv:fsiv97-20. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Jennifer Rontganger)

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.